LC
BIOT

Littlejohn & Co’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Littlejohn & Co’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$495K – 126
2022
Q2 		$495K Hold
50,000
– – 0.18% 38
2022
Q1 		$493K Hold
50,000
– – 0.13% 49
2021
Q4 		$492K Hold
50,000
– – 0.13% 46
2021
Q3 		$487K Hold
50,000
– – 0.14% 58
2021
Q2 		$484K Buy
+50,000
New +$486K 0.14% 66

Other funds holding BIOT

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231M AUM 3.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Littlejohn & Co's BIOT Position: Q3 2022 in Review

Littlejohn & Co sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2022, closing a stake of 50,000 shares — an estimated $495K sold.

Littlejohn & Co first reported a position in BIOT in Q2 2021 and held it in 5 quarters. The position peaked at $495K in Q2 2022. 69 funds tracked by Wall St. Rank hold BIOT as of Q3 2022.

  • Littlejohn & Co reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Littlejohn & Co sold 50,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2022, an estimated $495K.
  • Littlejohn & Co first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 5 quarters.
  • Littlejohn & Co's Biotech Acquisition Company Class A Ordinary Shares position peaked at $495K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2022.

Based on Littlejohn & Co's 13F filing for Q3 2022, filed 14 Nov 2022.